[Ref No. T02341]
University of Tasmania researchers have developed a novel microfluidic device for point-of-care (POC) analysis including therapeutic drug monitoring (TDM). Analytical targets can be selectively extracted, concentrated and purified using the novel method which combines electrokinetics and nanotechnology.
POC analysis enables more effective implementation of TDM, enabling individualised drug dosage based on measured drug levels in body fluids. At present, clinicians rely on transport of patient samples to a laboratory using techniques such as liquid chromatography tandem mass spectrometry (LC-MS/MS). Whilst this process takes typically too long (>18 hr) for effective clinical decision making, there are currently no portable systems available that are fast, affordable, have high specificity and sensitivity and that do not require professionally trained personnel.
Our novel device aims to address these issues by providing a cost effective solution that is fast, portable, safe and sensitive while using minute amounts of sample and reagents.
This technology is available for licensing or development opportunities to interested industry partners.
Proof of Principle
Prof Michael Breadmore, Dr Rosanne Guijt and Ms Aliaa Shallan from the Australian Centre for Research on Separation Science (ACROSS) at the University of Tasmania.
International Patent Application No. PCT/AU2015/050589
Shallan AI, Guijt RM, Breadmore MC, 2015, 'Electrokinetic Size and Mobility Traps for On-site Therapeutic Drug Monitoring', Angew Chem Int Ed Engl. 54(25):7359-62
Microfluidic device, therapeutic drug monitoring, point-of-care, nanochannels, small molecules, ampicillin, sepsis